Esomeprazole - AstraZeneca

Drug Profile

Esomeprazole - AstraZeneca

Alternative Names: D961H; Esomeprazole delayed-release capsules; Esomeprazole magnesium; Esoz; H-19918; H-19918 magnesium trihydrate; H199/18 magnesium trihydrate; Nexium; Nexium 24HR; Nexium Control; Nexium I.V.; Perprazole; S-omeprazole magnesium

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Daiichi Sankyo Company; Pfizer
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bleeding ulcer; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Jejunal ulcer; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Preregistration Stress ulcer

Most Recent Events

  • 20 Jun 2018 AstraZeneca plans a phase III trial for Reflux oesophagitis, Gastric ulcer and Duodenal ulcer in Japan (NCT03553563)
  • 18 Apr 2018 Launched for Duodenal ulcer (In children) in Japan (PO, Granules)
  • 18 Apr 2018 Launched for Gastric ulcer (In children) in Japan (PO, Granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top